Pangaea Oncology

Executive Summary

Pangaea Oncology is a Barcelona-based precision oncology company founded in 2015, operating a dual model of advanced molecular diagnostics services and R&D for novel diagnostic tools, particularly liquid biopsy and data analytics. The company aims to improve cancer patient outcomes by leveraging cutting-edge technology and scientific expertise. It provides services to both patients and pharmaceutical clients, positioning itself in the growing precision oncology market. However, as a private, pre-clinical company with no disclosed funding or revenue, its near-term visibility is limited. The lack of public financials and detailed product pipeline adds uncertainty, but its focus on liquid biopsy aligns with industry trends, and ongoing R&D could generate valuable intellectual property.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a pharmaceutical company for co-development of a liquid biopsy test60% success
• Q2 2027Completion of a Series A funding round to advance R&D pipeline70% success
• Q3 2027Publication of clinical validation data for a novel diagnostic tool50% success